Solid Tumors

Management of Hot Flashes in Patients with Breast Cancer on Anti-Estrogen-Based Therapy: The Role of Non-Hormonal Therapy

Berkin Kutluk, PharmD Candidate 2024, and Abigail Shockley, PharmD, BCOPIn patients with hormone-receptor (HR)–positive early-stage breast cancer, adjuvant endocrine therapy administered for up to 5 to 10 years significantly reduces…

Continue ReadingManagement of Hot Flashes in Patients with Breast Cancer on Anti-Estrogen-Based Therapy: The Role of Non-Hormonal Therapy

Advances in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: Current Landscape and Future Directions

Manali Bhave, MD Triple-negative breast cancer (TNBC) accounts for 15% to 20% of all breast cancer cases1 and is characterized by aggressive disease associated with early recurrence and high mortality.…

Continue ReadingAdvances in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: Current Landscape and Future Directions

Our Approach to the Patient With Newly Diagnosed Resectable/Borderline Resectable Pancreatic Adenocarcinoma: From the Medical Oncology Perspective

Amanda Y. Tam, MS, FNP-BC The standard of care with curative intent for resectable or borderline resectable pancreatic adenocarcinoma involves surgery and then adjuvant chemotherapy. High-risk features include the following:…

Continue ReadingOur Approach to the Patient With Newly Diagnosed Resectable/Borderline Resectable Pancreatic Adenocarcinoma: From the Medical Oncology Perspective